DVC1 0101

Drug Profile

DVC1 0101

Alternative Names: Angiogenic-gene-therapy-ID-Pharma; DVC1-0101; Fibroblast growth factor 2 gene therapy - ID Pharma; SeV-10101; SEV1-0101

Latest Information Update: 18 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator DNAVEC Corporation
  • Developer ID Pharma; Kyushu University
  • Class Gene therapies; Nucleic acids
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor expression modulators; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Intermittent claudication; Peripheral ischaemia

Most Recent Events

  • 22 Nov 2016 Phase-I/II clinical trials in Intermittent claudication in Australia (IM) (ACTRN12615001144505)
  • 22 Nov 2016 Phase-I/II clinical trials in Peripheral ischaemia in Australia (IM) (ACTRN12615001144505)
  • 08 Jun 2016 ID Pharma plans a phase I/IIa trial for Intermittent claudication and Peripheral ischaemia in Australia (IM) (ACTRN12615001144505)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top